No Data
Express News | Reported Earlier, Exicure And Adbiotech Partner To Evaluate Burixafor Combination Therapies In Multiple Indications Including Sickle Cell Disease And Acute Myeloid Leukemia
Exicure, Inc. and Adbiotech Co., Ltd. Announce Co-Development Agreement for Burixafor Combination Therapies
Exicure Strengthens Leadership With New COO and Director
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Exicure Reaches Preliminary Settlement in Derivative Lawsuits
Express News | Exicure Inc - Announces Settlement of Stockholder Derivative Action per March 18, 2026 Stipulation
